 This study proposes a new approach to enhance the efficacy of magnetic hypothermia immunotherapy. It combines the use of superparamagnetic iron oxide nanoparticles, SBIOs, which are known to have antitumor effects when heated, with a phase transition agent, PFP, an immune adjuvant, Resiquimode, to reduce the temperature threshold required for effective heat generation. This allows for more efficient delivery of heat to the target area while minimizing damage to surrounding healthy tissue. Additionally, the study found that this combination can also increase the expression of kaureticulin and HMGB1, two proteins associated with inflammation and immunity, respectively. These findings suggest that this hybrid system may be able to improve the efficacy of magnetic hypothermia immunotherapy by increasing the number of dendritic cells and cytotoxic T lymphocytes present at the tumor site. This article was authored by Chiaoxiqin, Yangju, Pan Li, and others. We are article.tv, links in the description below.